256 related articles for article (PubMed ID: 27463020)
1. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
2. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
3. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
[TBL] [Abstract][Full Text] [Related]
4. A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma.
Kubota S; Yoshida T; Kageyama S; Isono T; Yuasa T; Yonese J; Kushima R; Kawauchi A; Chano T
World J Surg Oncol; 2020 Oct; 18(1):270. PubMed ID: 33092599
[TBL] [Abstract][Full Text] [Related]
5. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis.
Gao H; Dong B; Liu X; Xuan H; Huang Y; Lin D
Anal Chim Acta; 2008 Aug; 624(2):269-77. PubMed ID: 18706333
[TBL] [Abstract][Full Text] [Related]
6. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
7. Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up.
Somani BK; Nabi G; Thorpe P; N'Dow J; Swami S; McClinton S;
Eur Urol; 2007 May; 51(5):1289-95; discussion 1296-7. PubMed ID: 17081679
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
9. Neuron-specific enolase: a serum tumor marker in renal cell carcinoma?
Gross AJ; Michl UH; Bornhöft G; Dieckmann KP
Eur Urol; 1993; 24(3):397-9. PubMed ID: 8262110
[TBL] [Abstract][Full Text] [Related]
10. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
11. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
[TBL] [Abstract][Full Text] [Related]
12. Prolyl hydroxylase-3 is a novel renal cell carcinoma biomarker.
Kim KH; Lee HH; Yoon YE; Na JC; Kim KS; Han WK
Investig Clin Urol; 2019 Nov; 60(6):425-431. PubMed ID: 31692952
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.
Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME
J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228
[TBL] [Abstract][Full Text] [Related]
14. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment of renal cell carcinoma with vena cava tumor thrombi].
Li XF; Zhou FJ; Qiu SP; Liu ZW; Wu RP; Huang K; Mei H
Ai Zheng; 2004 Sep; 23(9):1074-6. PubMed ID: 15363205
[TBL] [Abstract][Full Text] [Related]
16. Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential.
Huber J; Winkler A; Jakobi H; Bruckner T; Roth W; Hallscheidt P; Daneshvar K; Hohenfellner M; Pahernik S
Urol Oncol; 2014 Jan; 32(1):37.e1-6. PubMed ID: 23587431
[TBL] [Abstract][Full Text] [Related]
17. Midterm results of percutaneous microwave ablation under ultrasound guidance versus retroperitoneal laparoscopic radial nephrectomy for small renal cell carcinoma.
Yu J; Zhang G; Liang P; Yu XL; Cheng ZG; Han ZY; Zhang X; Dong J; Li QY; Mu MJ; Li X
Abdom Imaging; 2015 Oct; 40(8):3248-56. PubMed ID: 26288264
[TBL] [Abstract][Full Text] [Related]
18. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
19. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy.
Yoon HJ; Paeng JC; Kwak C; Park YH; Kim TM; Lee SH; Chung JK; Edmund Kim E; Lee DS
Ann Nucl Med; 2013 Oct; 27(8):748-55. PubMed ID: 23818007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
